How we work
Delvant deliverables are scoped by the question, not by the calendar. Below is the full ladder. Pick by question shape first, by investment second. Every tier ships with the same provenance discipline: per-claim tier classification, locked anchor sources, declared methodology.
Best for: “Show me what a Delvant report actually looks like before I commission one.”
Best for: “I have ONE specific question about a class, asset, or competitive position.”
Best for: “I have 2-3 connected questions that need scenario framing and stakeholder triangulation.”
Best for: “I need rolling competitive reads on a fixed cadence, not one-off commissions.”
Available to Tier 2 clients first. Public availability Q4 2026.
Best for: “Multiple non-competing firms in the same therapeutic area want to share fixed costs on a rolling intelligence read.”
Onboarding founding members 2027. Register interest via contact form.
Who builds this
Founder, Delvant. Vienna, AT.
Delvant is a single-founder practice. Every commissioned deliverable is built end-to-end by the founder: scoping the question, running the searches, classifying every claim, writing the dossier, signing the pre-delivery checklist. No junior analyst layer, no offshore drafting, no template farm.
That is the point. Boutique clinical-intelligence work fails when the named expert sells the engagement and a team of analysts produces the report. Here, the person who scopes the question is the person who writes the answer.
Methodology, source-locking discipline, and the LLM-council adversarial review process are built in-house and documented in every deliverable. The two-gate pre-delivery checklist (deep-research verification + adversarial review) is signed before any PDF ships.
Five rules that hold across every paid deliverable. None of them are optional.
Every claim in every deliverable is labelled SOURCED, INFERRED, OPINION, or HEDGED. Readers always know the analytical posture.
EMA, FDA, ClinicalTrials.gov, PubMed, EHA, ASH, EULAR, AACR, ASCO, ESMO. Secondary sources flagged. Internal forecasts always labelled.
Gate A = deep-research verification pass. Gate B = LLM-council adversarial review. No PDF ships without both gates green.
Every deliverable includes a methodology section: what was queried, what was excluded, what confidence interval applies. Redacted only in free public excerpts.
Snapshots older than 90 days carry a staleness banner. Source dates locked at delivery. Re-snapshot is a separate engagement.
No quarterly sales forecasts. No investment recommendations. No single-asset hit pieces. No identified KOL critique in public surfaces. No recycled syndicated content.
Three categories of provider serve adjacent buyers. Delvant occupies the middle.
Tier 1 competitive briefs start at EUR 3,500 (10-15 pages, 1 question, 5 business days). Tier 2 strategic dossiers run EUR 12,000-35,000 (20-30 pages, 2-3 questions, 10-15 business days). Tier 3 quarterly retainers (from Q4 2026) and Tier 4 indication-cluster consortia (from 2027) price separately. Free public excerpts are available on the sample-reports section.
Tier 1 briefs ship in 5 business days from kick-off. Tier 2 dossiers ship in 10-15 business days, with a mid-draft checkpoint at day 8-12 for framing review. Turnaround is fixed - we do not compress 10-day projects to 3 days for a rush fee.
Every claim carries a per-claim provenance tag: Sourced (direct primary citation, page-locked), Inferred (cross-trial or indirect inference, basis stated), Opinion (analytical interpretation, not data), or Hedged (low-confidence signal). Anchor sources are locked: ClinicalTrials.gov, EMA, FDA, PubMed, plus EHA, ASH, EULAR, AACR, ASCO, ESMO congress abstracts. Every Sourced claim is re-verified at the cited URL before delivery (Gate A).
Yes. Delvant uses LLM-driven retrieval and synthesis under documented human oversight. Every cited claim is verified at source (Gate A), every analytical claim passes LLM-council adversarial review (Gate B), and every claim ships with a provenance tag. Delvant acts as an AI deployer under EU AI Act Article 4. Client data is never used to train external models.
Data platforms (Evaluate, Clarivate Cortellis, Citeline, GlobalData) sell templated syndicated reports and database subscriptions; their strength is dataset breadth, their trade-off is opaque methodology and off-the-shelf framing. Strategy consultancies (L.E.K., Trinity, ZS, Putnam, IQVIA Consulting) run bespoke multi-month engagements at EUR 200K-2M with senior judgment but 8-12 week cycles. Delvant occupies the gap: bounded custom deliverables at EUR 3,500-35,000, 5-10 business day turnaround, per-claim tier classification, locked anchor sources.
Core focus is rare hematology, immune cytopenias (ITP, AIHA, HDFN), and plasma-derived therapeutics. Adjacent coverage includes rare oncology, IgG-mediated autoimmune disease, and transplant. We deliberately stay narrow to maintain provenance quality; questions outside scope are referred to better-fit providers.
One free reframe pass is included after C3 final delivery, within 14 days. Reframing the same data through a different lens (regional, line-of-therapy, payer-cut) is free. Adding new comparators, re-running analysis against a different patient population, or removing Sourced findings is out of scope. Hard misses (wrong molecule, wrong indication) get 100 percent refund plus redo at cost.
No. Delvant reports are intelligence products, not regulatory submissions, medical advice, or investment recommendations. They inform commercial, medical-affairs, and BD decision-making. For regulatory filings, commission a CRO or your QA team. For investment advice, consult a licensed financial advisor.
30 minute scoping call. We tell you which tier fits, or that none of them do.
Book a scoping call View sample first